Viewing Study NCT05650060


Ignite Creation Date: 2025-12-25 @ 2:15 AM
Ignite Modification Date: 2026-03-04 @ 9:54 PM
Study NCT ID: NCT05650060
Status: COMPLETED
Last Update Posted: 2023-04-06
First Post: 2022-12-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
Sponsor: Novartis Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Plaque Psoriasis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None secukinumab, View
None psoriasis, View
None effectiveness, View
None real-world, View
None Thailand View